Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.
Paul Hudson has laid out his vision for Sanofi and it does not include diabetes or me-too products.
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
The first in-depth look Roche’s anti-CD20 bispecific, mosunetuzumab, reveals some very encouraging response rates, even in patients who failed Car-T therapy.
The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Today’s deal with Blueprint gives Ipsen two shots at Fop, but makes its takeout of Clementia look even more expensive.